AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
ACB   11.77 (-3.21%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
BA   173.28 (-3.78%)
AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
ACB   11.77 (-3.21%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
BA   173.28 (-3.78%)
AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
ACB   11.77 (-3.21%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
BA   173.28 (-3.78%)
AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
ACB   11.77 (-3.21%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
BA   173.28 (-3.78%)
Log in

NASDAQ:THORSynthorx Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$67.99
0.00 (0.00 %)
(As of 01/23/2020)
Add
Compare
Today's Range
$67.99
Now: $67.99
$67.99
50-Day Range
$67.99
MA: $67.99
$67.99
52-Week Range
$11.05
Now: $67.99
$71.90
VolumeN/A
Average Volume474,507 shs
Market Capitalization$2.20 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.
Read More
Synthorx logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.11 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:THOR
CUSIP88517530
Phone858-750-4700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.72 per share

Profitability

Net Income$-56,610,000.00

Miscellaneous

Employees39
Market Cap$2.20 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive THOR News and Ratings via Email

Sign-up to receive the latest news and ratings for THOR and its competitors with MarketBeat's FREE daily newsletter.

Synthorx (NASDAQ:THOR) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Synthorx?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthorx in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Synthorx.

How were Synthorx's earnings last quarter?

Synthorx Inc (NASDAQ:THOR) posted its quarterly earnings results on Tuesday, November, 5th. The medical instruments supplier reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.12. View Synthorx's earnings history.

What price target have analysts set for THOR?

4 Wall Street analysts have issued 12-month price objectives for Synthorx's stock. Their forecasts range from $30.00 to $68.00. On average, they expect Synthorx's share price to reach $50.25 in the next year. This suggests that the stock has a possible downside of 26.1%. View analysts' price targets for Synthorx.

Has Synthorx been receiving favorable news coverage?

Headlines about THOR stock have been trending somewhat negative recently, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Synthorx earned a news impact score of -1.6 on InfoTrie's scale. They also assigned media coverage about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news about Synthorx.

Who are some of Synthorx's key competitors?

What other stocks do shareholders of Synthorx own?

Who are Synthorx's key executives?

Synthorx's management team includes the following people:
  • Dr. Laura K. Shawver, CEO, Pres & Director (Age 61)
  • Dr. Floyd E. Romesberg, Scientific Founder & Director (Age 53)
  • Dr. Marcos Milla Ph.D., Chief Scientific Officer (Age 56)
  • Dr. Joseph Leveque, Chief Medical Officer (Age 58)
  • Terry L. Button, VP & Director

When did Synthorx IPO?

(THOR) raised $100 million in an initial public offering on Friday, December 7th 2018. The company issued 9,100,000 shares at $10.00-$12.00 per share. Jefferies, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

What is Synthorx's stock symbol?

Synthorx trades on the NASDAQ under the ticker symbol "THOR."

What is Synthorx's stock price today?

One share of THOR stock can currently be purchased for approximately $67.99.

How big of a company is Synthorx?

Synthorx has a market capitalization of $2.20 billion. The medical instruments supplier earns $-56,610,000.00 in net income (profit) each year or ($6.59) on an earnings per share basis. Synthorx employs 39 workers across the globe.

What is Synthorx's official website?

The official website for Synthorx is www.synthorx.com.

How can I contact Synthorx?

Synthorx's mailing address is 11099 North Torrey Pines Road Suite 190, La Jolla CA, 92037. The medical instruments supplier can be reached via phone at 858-750-4700 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.